TECX fell -12.77% intraday to $31.07 from Friday's $35.62 close, during regular market hours. The decline came without any company-specific announcement; no earnings, pipeline, or analyst news from Tectonic Therapeutic.

QNRX surged +61.95% to $7.79 during regular trading, up from a prior-session close of $4.81, extending an earlier ~45% premarket gain. Primary catalyst: positive interim Phase 2/3 data for QRX003 in Netherton Syndrome, with the primary endpoint met with statistical significance (4 of 6 patients achieved ≥1-grade IGA improvement, p=0.0087).

BioNTech shares are down -8.0% to $102.49, extending a drop that began in premarket trading after the company said it would end its Phase 2 colorectal cancer trial. The announcement triggered a roughly -10% premarket decline, with the stock remaining sharply lower into the regular session.

BHVN shares fell -5.96% during regular trading to $15.94, pulling back after Wednesday's roughly +18% surge to $16.95. The decline reflects profit-taking following the prior session's rally on the up to $795 million SK Biopharmaceuticals licensing deal for its Kv7 epilepsy platform.

SCTX fell -9.87% to roughly $28.57 intraday versus its prior close of $31.70, with the decline occurring during regular market hours. The move extends a post-IPO unwind: shares ran from the $15.00 July 24 IPO price to a $39.60 high on Aug 20 before momentum reversed, including a -16% drop on Aug 25.

SYRE fell -13.8% to $92.54, extending an after-hours drop that began Tuesday after the Phase 2 SKYWAY rheumatoid arthritis (RA) readout. The primary catalyst: SPY072 (a TL1A inhibitor) beat placebo but missed the company's internal efficacy bar, so Spyre will not advance it as an RA monotherapy.

GENB fell -16.78% to roughly $16.96 during regular market hours, reversing the prior session's +15% surge to $20.38. The primary catalyst is the expiration of the post-IPO lock-up, freeing roughly 103 million restricted shares (about 80% of shares outstanding) for potential sale by insiders and early investors.

SYRE fell -14.74% to $91.54, down from the prior session's close of $107.36, with the decline beginning in premarket trading and extending into the regular session. The primary catalyst was topline data from the Phase 2 SKYWAY-RA sub-study of SPY072, which met statistical significance on key endpoints but did not meet the company's internal bar to prioritize SPY072 as an RA monotherapy.

Sionna Therapeutics (SION) shares have fallen roughly 86% over the last 30 days, driven almost entirely by a single-day collapse following disappointing clinical trial data. The decline followed the failure of SION-719, the company's lead cystic fibrosis candidate, in a Phase 2a proof-of-concept trial announced in August 2026.

YARW shares have gained roughly 55% over the last 30 days, climbing from about $25.45 to near $39.50. The advance followed Yarrow Bioscience's Nasdaq debut after completing its merger with VYNE Therapeutics in late July 2026.

INO shares are up +7.63% intraday, trading near $1.27 versus a $1.18 prior close, during regular market hours. The primary catalyst is a newly announced collaboration with Akeso, Dana-Farber Cancer Institute, and Mass General Brigham to evaluate Akeso's cadonilimab combined with Inovio's DNA medicine INO-5412 in glioblastoma.

Northwest Biotherapeutics (NWBO) trades near $0.18 per share on the OTCQB, within a 52-week range of roughly $0.14 to $0.37, after a modest, single-digit move over the trailing 30 days. The company's core asset is DCVax-L, a personalized dendritic-cell therapy that completed a 331-patient Phase III trial in glioblastoma (GBM) and was published in JAMA Oncology.

RGNX is down roughly -23.6% to $8.19 from a prior close of $10.72, with the selloff beginning in premarket trading and extending into Monday's regular session. The move was triggered by the FDA placing a clinical hold on RGX-121, the company's Hunter syndrome (MPS II) gene therapy, after asymptomatic spine MRI findings in five CAMPSIITE study participants.

OABI rose +0.70% (+$0.03) to close at $4.33 during Friday's regular trading session, extending a multi-day advance. The move continues momentum from the Aug. 17 Eli Lilly collaboration and license agreement, which offers up to $370M in milestone payments plus tiered royalties.

Silence Therapeutics shares rose roughly 20% over the 30-day period, driven by positive clinical data and a major capital raise. The biggest catalyst was positive Phase 2 topline results for divesiran in polycythemia vera, which sent the stock up about 29% in a single session to a 52-week high.

Achieve Life Sciences (ACHV) rose roughly 31% over the last 30 days, from a closing price near $6.10 in late July to about $7.99 by late August. The gain extended a broader advance of approximately 70% over the past three months, driven by progress on the company's cytisinicline regulatory pathway.

CTNM rose +7.30% in the latest regular session, closing at $17.19 (from a $16.02 prior close) and touching a new 52-week high of $17.35. The rally extended a multi-week uptrend tied to lead asset PIPE-791 (LPA1 antagonist), now in the global Phase 2 PROPEL-IPF trial for idiopathic pulmonary fibrosis.

SGMT shares climbed roughly 45% over the last 30 days, from a closing price near $7.07 in late July to $10.25 by the August 21 close. The move extends a broader rally, with the stock up more than 40% over the trailing quarter and roughly 73% year to date.

Entera Bio (ENTX) shares climbed roughly 59% over the trailing 30 days, rising from about $2.03 on July 22 to $3.23 as of the most recent close. The move was driven primarily by U.S. FDA alignment on a single registrational Phase 3 trial for its lead candidate EB613 and a $275 million private placement completed in July 2026.

The target: $10 per share, a psychological round-number milestone roughly 16% above MRVI's latest close near $8.64. Bullish case: A sharp earnings-driven rally, accelerating GMP (Good Manufacturing Practice) consumables demand, expanding margins, and a materially strengthened balance sheet.